|

BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study

ByPsychedelic Spotlight

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.

Timestamps:

0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #CMPS #PsychedelicTherapy

Similar Posts

  • Investing in Psychedelic Stocks 101 [ Interview With The Medicine Of Being Human]

    Listen, Videos

    Hello Psychedelic Investors! As I mentioned in the previous episode of the Psychedelic Investor, last week I had my first ever interview with the wonderful Sena who is interested in creating a resource for those new to investing in psychedelic stocks and investing in stocks in general.
    For those interested in the basics on psychedelic investing, you can watch the entire video on:
    The Medicine of Being Human :https://www.youtube.com/watch?v=p3d_t4GYG14&t=599s&ab_channel=TheMedicineofBeingHuman

    #PsychedelicStocks #MindMed #ThePsychedelicInvestor

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

  • Red Light Holland CANNABIS Merger, Atai IPO, NUMI Uplists, MindMed & More (TRUFF, atai, Numi, MMED)

    Listen, Videos

    LOTS of news happened this week, one of the major ones being Red Light Holland’s merger with a CANNABIS Company called Cresco. Other news we discuss in today’s segment is atai Life Sciences Nasdaq uplisting, MindMed’s new addition to the team, Numinus’ Uplisting and Field Trip’s upcoming financial results.

    Enjoy!

    Timestamps:

    0:00 – Intro
    1:00 – atai Life Sciences Nasdaq IPO
    2:56 -Red Light Holland Merging With A Cannabis Company & Acquisition
    7:26 -Numinus Wellness Uplists To The TSX
    8:45 – MindMed Appoints Peter Bergethon To Their Scientific Advisory Board
    10:36 – Field Trip’s Upcoming Financial Results

    Links:
    atai Life Sciences ( NASDAQ: atai)
    https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html

    Red Light Holland ( CSE: TRIP / OTC: TRUFF) Closes Acquisition of 80% of Happy Caps Mushroom Farm:
    https://ca.finance.yahoo.com/news/red-light-holland-closes-acquisition-122000805.html

    Red Light Holland is Merging with a Cannabis company called Creso Pharma to create The HighBrid Lab:
    https://www.newsfilecorp.com/release/87740/Creso-Pharma-and-Red-Light-Holland-Merge-to-Introduce-The-HighBrid-Lab-TM-a-Leading-Global-Psychedelics-x-Cannabis-Company-Specializing-in-Recreational-Products-Applied-Science-Technology-and-Innovation

    Numinus Wellness (OTC: LKYSF, TSX.V: NUMI) Uplists to Tier 1 on the TSX Venture Exchange:
    https://thecannabisstock.com/2021/06/18/numinus-wellness-gradu

    MindMed (NASDAQ: MNMD, NEO: MMED) Appoints Pharmaceutical Veteran, DR Peter Bergethon to their Scientific Advisory Board:
    https://www.prnewswire.com/news-releases/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-md-to-scientific-advisory-board-301314501.html

    Field Trip Health (OTC: FTRPF, TSX: FTRP) Will Release Financial Results for its fiscal fourth quarter and full year 2021 ended March 31, 2021:
    https://ca.movies.yahoo.com/field-trip-health-ltd-announces-131000469.html
    https://www.meetfieldtrip.com/news/news-details/2021/Field-Trip-Health-Ltd.-Schedules-Fiscal-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Conference-Call-for-Friday-June-25-2021-At-800-am-ET/default.aspx

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #RedLightHolland #MindMed #atai

  • AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

    Learn, Videos

    AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

    First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

    Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

    Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

    Timestamps:

    0:00 – Intro
    1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
    Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
    3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
    7:29 – Texas House Approves a Psychedelic Research Bill
    9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

    Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
    https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

    Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
    https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

    Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

    Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD